Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person"s parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person"s signs and symptoms, with testing done to rule out other potential causes.

According to our (Global Info Research) latest study, the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size was valued at US$ 336 million in 2023 and is forecast to a readjusted size of USD 569 million by 2030 with a CAGR of 7.9% during review period.

GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.

North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.

In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.

This report is a detailed and comprehensive analysis for global Amyotrophic Lateral Sclerosis (ALS) Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts, in consumption value ($ Million), 2019-2030

Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts by region and country, in consumption value ($ Million), 2019-2030

Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030

Global Amyotrophic Lateral Sclerosis (ALS) Treatment market shares of main players, in revenue ($ Million), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Amyotrophic Lateral Sclerosis (ALS) Treatment

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Amyotrophic Lateral Sclerosis (ALS) Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Amyotrophic Lateral Sclerosis (ALS) Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Riluzole
Edaravone (Radicava)
Other

Market segment by Application
Hospital
Drugs Store
Other

Market segment by players, this report covers
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Amyotrophic Lateral Sclerosis (ALS) Treatment product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Amyotrophic Lateral Sclerosis (ALS) Treatment, with revenue, gross margin, and global market share of Amyotrophic Lateral Sclerosis (ALS) Treatment from 2019 to 2024.

Chapter 3, the Amyotrophic Lateral Sclerosis (ALS) Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Amyotrophic Lateral Sclerosis (ALS) Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Amyotrophic Lateral Sclerosis (ALS) Treatment.

Chapter 13, to describe Amyotrophic Lateral Sclerosis (ALS) Treatment research findings and conclusion.